Notes
2019 US dollars
Reference
Kazi DS, et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation : 12 Feb 2020. Available from: URL: https://doi.org/10.1161/CIRCULATIONAHA.119.045093
Rights and permissions
About this article
Cite this article
Tafamidis not cost effective for transthyretin amyloid cardiomyopathy. PharmacoEcon Outcomes News 848, 29 (2020). https://doi.org/10.1007/s40274-020-6642-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6642-7